Amoy Diagnostics Co., Ltd. (300685.SZ)

17.95 -1.05 (-5.53%) At close: 03:04PM CST

Amoy Diagnostics Co., Ltd.

No. 39 Dingshan Road
Haicang District
Xiamen 361027
China
86 59 2680 6830
https://www.amoydx.com

Sector(s): Healthcare
Industry: Diagnostics & Research
Full-time employees: 1,119

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Ying Chen	CFO, Accounting Supervisor & Secretary to the Board of Directors	N/A	N/A	1970
Mr. Ruan Li	Deputy GM, CTO & Director	N/A	N/A	1978
Mr. Frank Ron Zheng	Deputy GM & Director	N/A	N/A	1990
Mr. Huibin Zheng	Deputy General Manager	N/A	N/A	1962
Mr. Jiemin Luo	GM & Director	N/A	N/A	1983
Ms. Fei Luo	Deputy GM & Director	N/A	N/A	1978

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CNY.

Description

Amoy Diagnostics Co., Ltd., a diagnostic company, focuses on development and commercialization of diagnostics product for oncology in China and internationally. It offers AmoyDx homologous recombination deficiency (HRD) focus panel solutions for evaluating PARP inhibitor-related biomarkers and advancing targeted treatment research in ovarian cancer; AmoyDx HRD complete panel to detect genetic aberrations across HRR genes and HRD status; AmoyDx master panel, a CGP assay; AmoyDx BRCA Pro panel that covers various protein coding regions, intron/exon boundaries, select introns, and UTR regions of the BRCA1 and BRCA2 genes; AmoyDx handle classic NGS panel to detect multiple gene mutations in cancer patients for treatment; and AmoyDx essential NGS panel to detect EGFR, ALK, ROS1, RET, KRAS, NRAS, PIK3CA, BRAF, HER2, and MET genes in patients with non-small cell lung cancer and colorectal cancer using FFPE or liquid biopsy samples. The company also provides AmoyDx handle HRR NGS panel for detection of somatic and germline variants; AmoyDx pan lung cancer PCR panel, a tissue-based real-time qPCR assay for in vitro diagnostics; AmoyDx myeloid blood cancer panel; AmoyDx comprehensive panel, a sequencing-based test capable of detecting a range of alterations; AmoyDx PD-L1 (E1L3N) assay; and AmoyDx handle melanoma NGS panel to detect single nucleotide variants, insertions, and deletions within pivotal melanoma tumor genes. In addition, it offers ALK gene fusions and ROS1 gene fusions, multi-gene mutations, EML4-ALK fusion gene, EGFR/ALK/ROS1 mutations, MET mutation, HER2 mutation, RET gene fusions, KRAS mutation, KRAS/NRAS mutations, NRAS mutation, KRAS/NRAS/BRAF mutations, BRAF mutation, PIK3CA five mutations, microsatellite instability, PIK3CA mutation, human papillomavirus genotyping, JAK2 mutation, TERT/HRAS mutations, EGFR 29 mutations, EGFR mutation, ROS1 gene fusions, NTRK gene fusions, BRAF V600 mutations detection kits, as well as DNA and RNA extraction kits under the Super-ARMS and AmoyDx names. The company was founded in 2008 and is based in Xiamen, China.

Corporate governance

Amoy Diagnostics Co., Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.